Literature DB >> 11223553

Pharmacodynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel.

H Minami1, Y Sasaki, T Watanabe, M Ogawa.   

Abstract

The entire time course of leukopenia after anticancer treatment is clinically more relevant than a singly measured nadir count. In order to identify factors associated with neutropenic fever, a mechanistic pharmacodynamic model with two compartments corresponding to leukocytes in bone marrow and peripheral blood was applied to describe the time course of leukopenia. Seventeen patients with breast cancer were treated with 210 mg / m(2) of paclitaxel infused over 3 h as a single agent in a phase II study. Adequate fitting of the time course of leukopenia was achieved in all patients, and time-dependent parameters, including the time period during which leukocyte counts remained below 2000 / microl and the area between the curve for time versus leukocyte counts and the line of a leukocyte count of 2000 / microl (A < 2000), were calculated in each patient. Leukopenia was not significantly correlated with pharmacokinetic parameters, including time above a threshold concentration or the area under the time-concentration curve. A negative correlation between age and the sensitivity parameter of the pharmacodynamic model was observed (r (2) = 0.21, P = 0.07). Patients who experienced neutropenic fever had a larger A < 2000 than patients who did not experience fever (4512 vs. 6 days / microl, P = 0.05), but fever was not significantly related to any pharmacokinetic parameter or the leukocyte nadir count. Febrile episodes were better associated with the time course of leukopenia than the singly measured nadir count, and the pharmacodynamic model presents a novel platform to analyze the entire time course of leukopenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223553      PMCID: PMC5926694          DOI: 10.1111/j.1349-7006.2001.tb01086.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  27 in total

1.  A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression.

Authors:  M O Karlsson; V Molnar; J Bergh; A Freijs; R Larsson
Journal:  Clin Pharmacol Ther       Date:  1998-01       Impact factor: 6.875

2.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

3.  Kinetic evaluation of the pool sizes and proliferative response of neutrophils in bacterially challenged aging mice.

Authors:  G Rothstein; R D Christensen; B R Nielsen
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

Review 4.  Pharmacodynamics in cancer therapy.

Authors:  M J Ratain; R L Schilsky; B A Conley; M J Egorin
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

5.  The hematopoietic microenvironment in the elderly: defects in IL-1-induced CSF expression in vitro.

Authors:  M A Lee; G M Segal; G C Bagby
Journal:  Exp Hematol       Date:  1989-10       Impact factor: 3.084

6.  Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Authors:  R Bruno; D Hille; A Riva; N Vivier; W W ten Bokkel Huinnink; A T van Oosterom; S B Kaye; J Verweij; F V Fossella; V Valero; J R Rigas; A D Seidman; B Chevallier; P Fumoleau; H A Burris; P M Ravdin; L B Sheiner
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 7.  Paclitaxel pharmacokinetics and pharmacodynamics.

Authors:  C M Kearns; L Gianni; M J Egorin
Journal:  Semin Oncol       Date:  1995-06       Impact factor: 4.929

8.  Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

Authors:  T Ohtsu; Y Sasaki; T Tamura; Y Miyata; H Nakanomyo; Y Nishiwaki; N Saijo
Journal:  Clin Cancer Res       Date:  1995-06       Impact factor: 12.531

9.  Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.

Authors:  H Minami; Y Ando; S Sakai; K Shimokata
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

10.  Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections.

Authors:  C Selig; W Nothdurft
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more
  6 in total

Review 1.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 2.  Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.

Authors:  Tore B Stage; Troels K Bergmann; Deanna L Kroetz
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

3.  Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.

Authors:  Markus Joerger; Stefanie Kraff; Alwin D R Huitema; Gary Feiss; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

4.  Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  AAPS PharmSci       Date:  2002

Review 5.  Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.

Authors:  Hend M Nawara; Said M Afify; Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Biomedicines       Date:  2021-05-02

6.  Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.

Authors:  R H J Mathijssen; J Verweij; W J Loos; P de Bruijn; K Nooter; A Sparreboom
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.